

Medication cost is significantly reduced after Roux-en-Y gastric bypass in obese patients

Ina GESQUIERE*, PharmD; Judith ARON-WISNEWSKY*, MD-PhD; Veerle FOULON, PharmD-PhD; Steeve HAGGE, PharmD; Bart VAN DER SCHUEREN, MD-PhD; Patrick AUGUSTIJNS, PharmD-PhD; Jean-Luc BOUILLOT, MD-PhD; Karine CLEMENT, MD-PhD; Arnaud BASDEVANT, MD-PhD; Jean-Michel OPPERT, MD-PhD; Marion BUYSE, PharmD-PhD

*Ina Gesquiere and Judith Aron-Wisnewsky have equally contributed to this work.

Manuscript type: Original contribution

Correspond to: Ina Gesquiere

Authors:

Ina Gesquiere, PharmD

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

O&N II, Herestraat 49, box 521

3000 Leuven

Belgium

Phone: + 32 16 32 34 47

Fax: + 32 16 32 34 68

E-mail: ina.gesquiere@pharm.kuleuven.be

Judith Aron-Wisnewsky, MD-PhD

1. Institute of Cardiometabolism and Nutrition, ICAN, AP-HP, Pitié-Salpêtrière hospital, F-75013, Paris, France 83 boulevard de l'Hôpital 75013 Paris, France

26 2. Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1166 I, ICAN, Nutriomics team, F-
27 75005, Paris, France;

28 3. INSERM, UMR_S U1166, Nutriomics team, F-75013, Paris, France;

29 e-mail: judith.aron-wisnewsy@psl.aphp.fr

30

31 **Veerle Foulon , PharmD-PhD**

32 Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

33 O&N II, Herestraat 49, box 521

34 3000 Leuven

35 Belgium

36 e-mail: veerle.foulon@pharm.kuleuven.be

37

38 **Steeve Haggege , PharmD**

39 Clinical pharmacy Laboratory, Faculty of Pharmacy,

40 University Paris XI

41 5, rue Jean Baptiste Clément

42 92296 Chatenay-Malabry

43 e-mail: hasteeve@gmail.com

44

45 **Bart Van der Schueren, MD-PhD**

46 1. Clinical and Experimental Endocrinology, KU Leuven

47 2. Department of Endocrinology, KU Leuven/University Hospitals

48 Leuven, Campus Gasthuisberg, Herestraat 49, Box 7003,

49 3000 Leuven, Belgium

50 e-mail: bart.vanderschueren@uzleuven.be

Patrick Augustijns, PharmD-PhD

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

O&N II, Herestraat 49, box 921

3000 Leuven

Belgium

e-mail: patrick.augustijns@pharm.kuleuven.be

Jean-Luc Bouillot, MD-PhD

Visceral surgery Department, Ambroise Paré (AP-HP)

9, avenue Charles de Gaulle

92104 Boulogne-Billancourt cedex

e-mail : jl.bouillot@apr.aphp.fr

Karine Clément, MD-PhD

1. Institute of Cardiometabolism and Nutrition, ICAN, AP-HP, Pitié-Salpêtrière hospital, F-

75013, Paris, France 83 boulevard de l'Hôpital 75013 Paris, France

2. Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1166 I, ICAN, Nutriomics team, F-

75005, Paris, France;

3. INSERM, UMR_S U1166, Nutriomics team, F-75013, Paris, France;

e-mail: karine.clement@psl.aphp.fr

Arnaud Basdevant, MD-PhD

1. Institute of Cardiometabolism and Nutrition, ICAN, AP-HP, Pitié-Salpêtrière hospital, F-

75013, Paris, France 83 boulevard de l'Hôpital 75013 Paris, France

75 2. Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1166 I, ICAN, Nutriomics team, F-
76 75005, Paris, France;

77 3. INSERM, UMR_S U1166, Nutriomics team, F-75013, Paris, France;

78 e-mail : arnaud.basdevant@psl.aphp.fr

79

80 **Jean-Michel Oppert, MD-PhD**

81 1. Institute of Cardiometabolism and Nutrition, ICAN, AP-HP, Pitié-Salpêtrière hospital, F-
82 75013, Paris, France 83 boulevard de l'Hôpital 75013 Paris, France

83 2. Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1166 I, ICAN, Nutriomics team, F-
84 75005, Paris, France;

85 e-mail : jean-michel.oppert@psl.aphp.fr

86

87 **Marion Buyse, PharmD-PhD**

88 1. Clinical pharmacy Laboratory, Faculty of Pharmacy,

89 University Paris XI

90 5, rue Jean Baptiste Clément

91 92296 Chatenay-Malabry

92 2. Pharmacy Department, Saint Antoine hospital (AP-HP)

93 University Pierre et Marie Curie- (UPMC), Paris 6

94 184, rue du Faubourg St Antoine

95 75012 Paris

96 3. Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS 938

97 University Pierre et Marie Curie-(UPMC) Paris 6,

98 Centre de recherche de Saint Antoine

99 75012 Paris

100 e-mail: marion.buyse@u-psud.fr

101

102 **Running head:** Medication use after RYGB

103

104 **Acknowledgements**

105 Ina Gesquiere receives a PhD grant of the Agency for Innovation by Science and Technology,

106 Flanders, IWT-111328. Judith Aron-Wisnewsky received a grant from Nestle and Appert.

107 The authors declare no conflict of interest.

108

Abstract

Objective: To determine the influence of Roux-en-Y gastric bypass (RYGB) on medication-related costs.

Methods: Analysis of types, dosages and costs of drugs and medical devices prescribed before and after surgery (1, 3, 6, 12 months and yearly thereafter) in patients who underwent RYGB between June 2004 and May 2010, and had an outpatient visit between December 2009 and May 2010 at Pitié-Salpêtrière University Hospital, Paris, France.

Results: The cohort included 143 patients (78% female, mean age 42.9 years, mean BMI 48.6 kg/m²). Total prescription costs were significantly lower (-32%, $p<0.001$) one year after RYGB compared with preoperative costs. However, the cost for medications to prevent RYGB side effects (in particular nutritional deficiencies) displayed a 36-fold increase in the first month post-surgery, but then decreased progressively over time. Importantly, the cost related to the treatment of the two most frequent obesity-related diseases significantly decreased one year after surgery. Indeed, prescription costs for treatment of type 2 diabetes (T2D) and obstructive sleep apnea (OAS) (namely CPAP therapy considered as the gold standard treatment) were reduced one year after surgery by 85% and by 63% (both $p<0.001$), respectively. We also observed a trend toward a decrease in the prescription costs of other obesity-related diseases, although it didn't reach significance in our cohort.

Conclusions: Considering medication to treat both obesity-related diseases and prevention of secondary effects of bariatric surgery, we observed that overall post-operative medication costs were significantly reduced one year after surgery, especially for T2D and OSA.

Abstract words: 244

Keywords: Medication cost – Prescriptions – Obesity – Comorbidities - Bariatric surgery – Roux-en-Y gastric bypass

Introduction

The prevalence of obesity has increased worldwide over the last decades [1], thereby also increasing the prevalence of obesity-related diseases (such as type 2 diabetes mellitus (T2D), dyslipidemia, hypertension, cardiovascular diseases (CVD), but also obstructive sleep apnea (OSA), asthma, joint arthritis, and depression) [2]. Therefore, obese individuals are prone to increased consumption of drugs compared to lean individuals [3].

Medical management of obesity has proven disappointing on both the amount of weight loss and its maintenance over time [4]. Therefore, the number of patients undergoing bariatric surgery such as Roux-en-Y gastric bypass (RYGB), which is indicated for the most severe form of obesity, has increased dramatically. Most importantly, it is currently the only efficient mean to achieve major and sustainable weight reduction [2,5]. Along with a significant reduction in all-cause mortality, RYGB improves several obesity-related diseases [6-10], leading to a decreased consumption of related treatments [11]. Indeed, medication used for T2D, hypertension and dyslipidemia decreased significantly as early as 1 year post-surgery (by 76%, 51% and 59%, respectively) [12]. This reduction continued significantly 3 years post-surgery, in particular for T2D, dyslipidemia and CVD [11]. Finally, comparing obese patients post-surgery to an obese matched control group, the SOS study, demonstrated a significant reduction in the cost of drugs for obesity-related diseases after 7 years, which remained significantly lower during 20 years of follow-up [13].

Although beneficial regarding mortality and obesity-related comorbidities, RYGB induces potential risks such as nutritional deficiencies and short term surgical complications such as venous thrombosis, anastomosis ulceration and gallstones [16-18].

Both can be prevented by specific drug prescriptions such as daily vitamin and mineral substitution [14,15], hence inducing substantial costs. Few studies (if any) have yet addressed the overall treatment cost evolution after surgery taking into account not only treatment of

obesity-related diseases but also surgery side effects' prevention. As it remains unclear to what extent RYGB may be cost-saving in terms of overall drug consumption, we aimed to examine the evolution of medication use and associated costs in RYGB patients.

Methods and procedures

Study design and data collection

We took advantage of an ongoing clinical research protocol (approved by the Ethics Committee of Hôtel-Dieu Hospital) including all of our bariatric surgery patients followed at the Nutrition Department of Pitié-Salpêtrière hospital Paris, France. All subjects gave written informed consent. Only those who underwent RYGB were included. Bariatric surgery was decided in agreement with international clinical practice guidelines [19]. For the purpose of the study, patients who had undergone a previous bariatric surgery, as well as those who didn't attend postoperative follow-up, were excluded.

We first retrospectively included all patients who had undergone RYGB from June 2004 to November 2009, and for whom clinical data (age, sex, BMI) were available in our database both before (baseline) and 1, 3, 6 months (M) and yearly (Y) after surgery, until 4 years post-RYGB, and who had a follow-up visit. We also prospectively included patients who came for a RYGB preoperative examination between December 2009 and May 2010. Data were collected from patient's medical records and verified with the patient at the inclusion visit. Entire obesity-related diseases history and complete list of drugs and medical devices prescribed at each examination (including Continuous Positive Airway Pressure (CPAP), considered as the gold standard treatment of OSA) [20] was retrieved. The dosing regimen for each drug was also collected.

Data analysis

We tabulated drugs taken by each patient at each follow-up time point, including cost per month (in euros). The cost for each medication or medical device was obtained from the

official current price list (<http://www.theriaque.org> and www.ameli.fr) and when appropriate, generic drug costs for the largest package available, were used. Treatments were divided into curative use (further grouped according to the different obesity-related diseases they were used for (including CPAP treatment)), or preventive use (those to prevent surgery-related complications or potential nutritional deficiencies). The different categories of obesity-related diseases were defined upon medication use and thorough checking of the adequacy with each patient's medical history. Patients with T2D were defined as those on oral anti-diabetic therapy and/or insulin and/or GLP-1 analogue. OSA included patients on CPAP treatment. CVD comprised antihypertensive drugs and/or antiplatelet agents and included secondary CVD prevention drugs. Dyslipidemia included patients treated with statin or fibrates. Psycho- and neurological disorders comprised patients who were on antidepressant therapy and those with anti-epileptic treatment. Lastly, a category called "other" included patients using pain killers, drugs used for asthma, hyperuricemia, skin complications, urinary incontinence or gastrointestinal problems.

We used the Anatomical Therapeutic Chemical classification system (ATC-system), which categorizes drugs into different classes according to their therapeutic and chemical characteristics, at the first level, except for drugs used in metabolic disorders, which were classified at level 2 of the ATC-system (<http://www.whocc.no/>). Prevention treatment at our center has previously been described [13] and includes 2 weeks before surgery: vitamin D (once 4x100000IU), vitamin B1 (250mg/day), vitamin B12 (250µg/day) and esomeprazole (40mg/day). Esomeprazole dosing is maintained during 6 months post-surgery to prevent anastomosis ulcerations. Enoxaparin (4000IU 1inj/day) is prescribed for 3 weeks post-surgery to prevent venous thrombosis. Fifteen days post-RYGB, vitamin and mineral supplements including Azinc optimal® (2x/day), iron (2x80mg/day), vitamin D (800IU/day) and calcium (1000mg/day) are started and continued on the long term. Ursodeoxycholic acid

is introduced 2 weeks post-surgery (only for patients with no previous history of cholecystectomy) and continued for 3 months to prevent gallstone formation known to be associated with major and rapid weight loss [16-19]. Besides this standard protocol, additional drugs and/or supplements to treat side effects related to surgery (vitamins, minerals and proteins, antiemetics,...) can be added on an individually-tailored basis.

Statistical analysis

Continuous variables are presented as mean \pm SD. The main outcome variables were the changes in the relative cost of each comorbidity treatment, calculated both in the whole cohort or considering only those patients affected with the comorbidity in question. Changes in (i) the total cost and (ii) the medication cost for both preventive and curative use were evaluated. Medication costs 1, 3, 6, 12, 24, 36 and 48 months after RYGB were compared with those at baseline. Two-way ANOVA and Chi-² tests were used. Statistical significance was set at $p < 0.05$.

Results

We included 143 patients whose characteristics are displayed in Table 1. BMI gradually decreased during the first year post-RYGB and then stabilized up to four years (48.6 ± 9 kg/m² vs. 33.2 ± 8 kg/m²) (Figure 1) (ie: mean weight loss 33 ± 18 kg).

When compared to baseline values, we observed a significant 32% reduction in the total prescription costs one year post-surgery ($p<0.01$) (Figure 2). Curative medications and medical device cost significantly decreased as early as one month post-surgery and onwards (Figure 3). The most significant reduction in the mean prescription cost concerned T2D and OSA treatments (Table 2). Indeed, 34% of patients were treated for T2D at baseline, which was reduced respectively to 16%, 11%, 9% and 0%, after 3 months, 1, 2 and 4 years after RYGB. Likewise, T2D treatment cost decreased by 65% ($p<0.01$) at 1 month, and further over time to reach 0€ four years post-RYGB (Table 3).

OSA mean treatment cost decreased significantly as early as 3 months post-surgery and onwards to reach its lowest cost (12.86€/month) at three years (ie: 89% reduction vs. baseline). By contrast, drugs for CVD and dyslipidemia's cost decreased more weakly (-51.5% and -81%, respectively), only reaching significance one and two years post-RYGB. We observed no significant change regarding other obesity-related disease prescriptions. As expected, preventive treatment's prescription just before the surgery induced a 36 fold increase in the cost one month post-surgery, compared with baseline. Although this cost decreased over time, but it remained significantly higher than baseline values, even after four years.

Discussion

This study aimed to investigate the overall medication costs after RYGB. We focused both on the costs of the different obesity-related diseases treatments, and those of treatments prescribed to prevent surgery-related complications, and observed a significant reduction in the global medication cost one year post-surgery and onwards, compared with baseline. This major post-surgery cost reduction was mainly explained by the acute decrease in T2D and OSA treatment prescriptions.

The marked reduction in T2D medication use observed in our study, resulted in an 85 fold decrease in medication cost one year post-RYGB among the patients with diabetes, which is in line with previous pharmaco-economic studies. Segal *et al* [12] evaluated medication use in 6,235 patients undergoing bariatric surgery and demonstrated 76% reduction in T2D medication use one year post-surgery that persisted up to four years [22]. A significant reduction in oral anti-diabetic agents and insulin therapy (80% and 79%) four years post-RYGB was also observed in another study, including 191 diabetic patients [23]. Although our cohort was of a smaller size, the reduction of T2D treatment is in line with a significant improvement or normalization of both HBA1c and fasting glycemia during follow-up.

Literature entails that RYGB enables (i) a 57.5% T2D remission [24] according to the definition [25], (ii) an 84% improvement in T2D status [26], and (iii) a reduction in the occurrence of T2D [27]. We herein demonstrate a significant cost reduction as soon as one month post-RYGB, in agreement with the rapid improvement of diabetes post-surgery which involves multiple mechanisms [28-30], some unrelated to weight loss [23,28,31].

OSA occurred in 33% of our patients at baseline. We observed a 63% reduction in the cost of CPAP one year post-RYGB, in line with previous studies [2,32-35]. Likewise, we confirmed the possibility to stop CPAP upon clinical examination and polysomnography. In contrast with T2D, OSA improvement only becomes apparent when substantial reduction in BMI occurs, suggesting the importance of maintained weight loss. Yet, as acknowledged by studies comparing the effects of surgical versus diet-induced weight loss [36], the improvement of OSA involves numerous mechanisms other than weight loss [37].

Bariatric surgery reduces all-cause mortality, particularly death from CVD [5,21,38] and improves CVD risk factors [10]. We herein confirm the decrease in medication cost for dyslipidemia and CVD, reaching significance one and two years post-RYGB. However, these reductions were not significantly sustained on the longer term, although our patients didn't regain weight over the four years follow-up (Figure 1). Previous reports showed that although 51% and 59% of the patients could stop their hypertension or dyslipidemia medications soon post-surgery [39,40], the incidence of both diseases tends to increase again on the longer term (two and ten years) [5]. The fact that in our study drugs that were used for secondary prevention of cardiovascular events were pooled with drugs for hypertension and CVD could be another reason for the observation that reductions in drug costs for CVD did not sustain over time. Secondary prevention treatment is expected not to be discontinued, even if clinical or biological parameters improve.

By contrast, we did not observe a significant decrease in psycho-neurological treatment costs, in line with previous reports [44]. Indeed no significant change in the prevalence of antidepressant prescription was observed in a retrospective study including 439 patients before and post-RYGB [44]. Likewise, we recently demonstrated that the physical, but not the mental component of quality of life significantly improved one year after surgery [46].

While medication costs for curative use decreased, preventive medication costs increased immediately post-surgery. This can be explained by the choice of prevention regimen in our department [15]. Although the cost for preventive medication decreased over time, daily minerals and vitamins should never be discontinued as the prevention of nutrient deficiencies is lifelong [15].

Overall, the strength of our study lies in the fact that the evolution of treatment costs for obesity-related diseases was confronted with clinical examination and biological parameters obtained at each follow-up time point. This highlights the need for frequent medical follow-up enabling healthcare professionals to adapt the treatment to patients' needs in order to avoid side effects, such as hypoglycemia with antidiabetic drugs. Furthermore, these patients should receive sufficient information about their medication use, and need frequent adaptation of the medication scheme after surgery to provide correct adherence. We deliberately chose to limit our analysis on the impact of RYGB only, since different bariatric surgery techniques induce different results in terms of obesity-related diseases improvement or remission, thus impacting on drug associated costs.

However, our study presents some limitations. The medication classification in preventive and curative use, and the different comorbidities, is rather arbitrary. Besides, the recruitment of patients in a university hospital reflects the most severe obese patients with worse conditions which might reinforce the beneficial cost's reduction we herein observe. To

309 generalize our findings, our results need to be verified in a more general population of
310 candidates to RYBG to validate whether they still hold true.

311 Finally, we decided to focus on treatment costs and didn't address other costs related to
312 surgery follow-up, such as hospital days and non-primary care visits, thus we cannot conclude
313 on the total health care costs. Some recent studies have however addressed this issue. The
314 SOS study demonstrated that hospital days and visits were significantly reduced from 7 years
315 and onwards after surgery when comparing surgery to non-surgery obese patients [13]. By
316 contrast, Weiner *et al* failed to observe any difference in overall health care costs between
317 surgery patients and a matched obese group [47]. Of note, in those two studies, multiple
318 bariatric surgeries were assessed including techniques that are known to induce surgical
319 reoperations such as lapband and vertical gastropasty.

321 **Conclusion**

322 In this study we took into account medications prescribed for obesity-related diseases and for
323 prevention of surgical and nutritional complications, thus reflecting everyday life post-RYGB.
324 Our study shows that RYBG induces a significant reduction of total medication costs, as early
325 as one year post RYGB, compared to baseline. Most importantly, the reduced medication cost
326 was maintained over time several years post-RYGB and appears mainly to be due to the
327 significant improvement of T2D and OSA. Hence, RYGB entails economic benefits by
328 reducing the costs and need for medication and medical devices.

330 **Acknowledgements**

331 Ina Gesquiere receives a PhD grant of the Agency for Innovation by Science and Technology,
332 Flanders, IWT-111328. Judith Aron-Wisnewsky received a grant from Nestle and Appert.
333 The authors declare no conflict of interest.

References

- [1] WHO. Obesity and overweight. 2012. Fact Sheet No.311. Accessed June 10, 2013.
- [2] Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292(14): 1724-1737.
- [3] Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med. 2002; 162(18): 2061-2069.
- [4] Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab. 2010; 12(11): 941-946.
- [5] Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012; 307(1): 56-65.
- [6] Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. Eur J Endocrinol. 2008;158(2):135-145.
- [7] Dixon JB, Straznicky NE, Lambert EA, et al. Surgical approaches to the treatment of obesity. Nat Rev Gastroenterol Hepatol. 2011; 8(8): 429-437.
- [8] Suter M, Donadini A, Romy S, et al. Laparoscopic Roux-en-Y gastric bypass: significant long-term weight loss, improvement of obesity-related comorbidities and quality of life. Ann Surg. 2011; 254(2): 267-273.
- [9] de Aquino LA, Pereira SE, de Souza SJ, et al. Bariatric surgery: impact on body composition after Roux-en-Y gastric bypass. Obes Surg. 2012; 22(2): 195-200.
- [10] Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012; 98(24): 1763-1777.

- [11] Cremieux PY, Ledoux S, Clerici C, et al. The impact of bariatric surgery on comorbidities and medication use among obese patients. *Obes Surg.* 2010; 20(7): 861-870.
- [12] Segal JB, Clark JM, Shore AD, et al. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. *Obes Surg.* 2009; 19(12): 1646-1656.
- [13] Neovius M, Narbro K, Keating C, et al. Health care use during 20 years following bariatric surgery. *JAMA.* 2012; 308(11): 1132-1141.
- [14] Gasteyger C, Suter M, Gaillard RC, et al. Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standard multivitamin supplementation. *Am J Clin Nutr.* 2008; 87(5): 1128-1133.
- [15] Poitou BC, Ciangura C, Coupaye M, et al. Nutritional deficiency after gastric bypass: diagnosis, prevention and treatment. *Diabetes Metab.* 2007; 33(1): 13-24.
- [16] Quesada BM, Kohan G, Roff HE, et al. Management of gallstones and gallbladder disease in patients undergoing gastric bypass. *World J Gastroenterol.* 2010; 16(17): 2075-2079.
- [17] Mason EE, Renquist KE. Gallbladder management in obesity surgery. *Obes Surg.* 2002; 12(2): 222-229.
- [18] Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. *Am J Surg.* 1995 Jan;169(1):91-6.
- [19] Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. *Am J Clin Nutr.* 1992; 55 (2 Suppl): 615S-619S.

- [20] Rossi VA, Winter B, Rahman NM, et al. The effects of Provent on moderate to severe obstructive sleep apnoea during continuous positive airway pressure therapy withdrawal: a randomised controlled trial. *Thorax*. 2013 Sep;68(9):854-9.
- [21] Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med* 2007; 357(8): 741-752.
- [22] Makary MA, Clark JM, Shore AD, et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. *Arch Surg*. 2010; 145(8): 726-731.
- [23] Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. *Ann Surg*. 2003; 238(4): 467-484.
- [24] Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med*. 2009; 122(3): 248-256.
- [25] Pournaras DJ, Aasheim ET, Sovik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. *Br J Surg*. 2012; 99(1): 100-103.
- [26] Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *N Engl J Med*. 2012; 366(17): 1567-1576.
- [27] Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. *N Engl J Med*. 2012; 367(8): 695-704.
- [28] Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. *Obes Surg*. 2005; 15(4): 474-481.
- [29] Dirksen C, Jorgensen NB, Bojsen-Moller KN, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. *Diabetologia*. 2012.

- [30] Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. *Endocrinology*. 2009; 150(6): 2518-2525.
- [31] Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. *Ann Surg*. 2004; 240(2): 236-242.
- [32] Varela JE, Hinojosa MW, Nguyen NT. Resolution of obstructive sleep apnea after laparoscopic gastric bypass. *Obes Surg*. 2007; 17(10): 1279-1282.
- [33] Grunstein RR, Stenlof K, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. *Sleep*. 2007; 30(6): 703-710.
- [34] Rasheid S, Banasiak M, Gallagher SF, et al. Gastric bypass is an effective treatment for obstructive sleep apnea in patients with clinically significant obesity. *Obes Surg*. 2003; 13(1): 58-61.
- [35] Haines KL, Nelson LG, Gonzalez R, et al. Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. *Surgery*. 2007; 141(3): 354-358.
- [36] Dixon JB, Schachter LM, O'Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. *JAMA*. 2012; 308(11): 1142-1149.
- [37] Ashrafian H, le Roux CW, Rowland SP, et al. Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures. *Thorax*. 2012; 67(5): 442-449.
- [38] Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. *N Engl J Med*. 2007; 357(8): 753-761.
- [39] Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric surgery on cardiovascular risk profile. *Am J Cardiol*. 2011; 108(10): 1499-1507.

- [40] Athyros VG, Tziomalos K, Karagiannis A, et al. Cardiovascular benefits of bariatric surgery in morbidly obese patients. *Obes Rev.* 2011; 12(7): 515-524.
- [41] Hooper MM, Stellato TA, Hallowell PT, et al. Musculoskeletal findings in obese subjects before and after weight loss following bariatric surgery. *Int J Obes (Lond).* 2007; 31(1): 114-120.
- [42] Prachand VN, Alverdy JC. Gastroesophageal reflux disease and severe obesity: Fundoplication or bariatric surgery? *World J Gastroenterol.* 2010; 16(30): 3757-3761.
- [43] Frezza EE, Ikramuddin S, Gourash W, et al. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. *Surg Endosc.* 2002; 16(7): 1027-1031.
- [44] Cunningham JL, Merrell CC, Sarr M, et al. Investigation of antidepressant medication usage after bariatric surgery. *Obes Surg.* 2012; 22(4): 530-535.
- [45] Roerig JL, Steffen K, Zimmerman C, et al. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. *Surg Obes Relat Dis.* 2012; 8(1): 62-66.
- [46] Julia C, Ciangura C, Capuron L, et al. Quality of life after Roux-en-Y gastric bypass and changes in body mass index and obesity-related comorbidities. *Diabetes Metab.* 2013; 39(2): 148-154.
- [47] Weiner JP, Goodwin SM, Chang HY, et al. Impact of bariatric surgery on health care costs of obese persons: a 6-year follow-up of surgical and comparison cohorts using health plan data. *JAMA Surg.* 2013 Jun;148(6):555-62.

Figure legends

Figure 1: Mean BMI \pm SD before and after RYGB. On the x-axis the number of patients at each time point of the follow-up is represented. (*before surgery is referred as preop, 1M: 1 month, 1Y: 1 year*)

Figure 2: Medication cost per month per person pre-and post-RYGB, subdivided in preventive and curative medication use; significant differences are shown in comparison with baseline costs. (*before surgery is referred as preop, 1M: 1 month, 1Y: 1 year*)

Figure 3: Mean cost per patient per month for the different comorbidities, among the patients who suffer from the comorbidity. (*before surgery is referred as preop, 1M: 1 month, 1Y: 1 year*)

Table legends

Table 1: Characteristics of the study cohort at baseline before RYGB surgery

Table 2: Medication cost per month (at each time point post RYGB compared to baseline)

Table 3: The different treatments for T2D before and after RYGB along the follow-up

468 **Table 1:** Characteristics of the study cohort at baseline before RYGB surgery

Patients characteristics	
<i>Total</i>	143
<i>Female, n (%)</i>	112 (78.3%)
<i>Age (y), mean \pm SD</i>	42.9 \pm 12
<i>BMI (kg/m²), mean \pm SD</i>	48.6 \pm 8.8
Obesity related diseases n (%)	
Type 2 diabetes	49 (34%)
Obstructive sleep apnea	47 (33%)
Cardiovascular disease	71 (50%)
Dyslipidemia	38 (27%)
Psycho- and neurological disorders	44 (31%)

469

Table 2: Medication cost per month (at each time point post RYGB compared to baseline)

Comorbidity	Number of patients at baseline	Average medication cost per month at baseline (€)	1 month post surgery (€)	3 months post surgery (€)	6 months post surgery (€)	1 year post surgery (€)	2 years post surgery (€)	3 years post surgery (€)	4 years post surgery (€)
Type 2 Diabetes	Patients with the comorbidity (n=49)	81.0	-52.6*** [-76.6;-28.7]	-63.3*** [-87.3;-39.4]	-66.0*** [-91.2;-40.8]	-69.2*** [-94.7;-43.7]	-67.4*** [-95.1;-39.6]	-75.35*** [-107.6;-43.1]	-81.0*** [-131.0;-31.1]
	All patients (n=143)	28.3	-20.2*** [-37.2;-3.2]	-23.3*** [-40.1;-6.6]	-24.2*** [-41.6;-6.9]	-24.9*** [-43.0;-6.8]	-24.48*** [-43.55;-5.4]	-26.7*** [-49.3;-4.1]	-28.3** [-57.2;0.55]
Obstructive sleep apnea	Patients with the comorbidity (n=47)	115.7	-14.1 [-36.9;8.7]	-21.5** [-44.3;1.3]	-50.8*** [-73.9;-27.7]	-72.7*** [-96.6;-48.8]	-91.8*** [-117.2;-66.3]	-102.8*** [-132.6;-73.1]	-101.2*** [-142.1;-60.4]
	All patients (n=143)	35.6	0.6 [-16.4;17.6]	-1.8 [-18.6;14.9]	-10.7 [-28.0;6.6]	-19.2*** [-39.4;-1.1]	-26.7*** [-45.8;-7.6]	-30.8*** [-53.4;-8.2]	-31.2*** [-60.0;-2.3]
Cardiovascular diseases	Patients with the comorbidity (n=71)	33.2	-3.9 [-23.0;15.2]	-9.4 [-28.5-9.7]	-7.4 [-27.0;12.1]	-13.6 [-33.6;6.4]	-17.1* [-37.7;3.4]	-12.3 [-36.4;11.8]	-5.5 [-37.6;26.6]
	All patients (n=143)	16.5	-2.7 [-19.7;14.2]	-5.9 [-22.3;11.3]	-4.0 [-21.3;13.4]	-6.2 [-24.3;11.9]	-7.4 [-26.5;11.7]	-4.3 [-26.9;18.3]	-1.6 [-30.5;27.3]
Dyslipidemia	Patients with the comorbidity (n=38)	27.1	-5.6 [-31.3;20.2]	-14.7 [-40.5;11.0]	-17.9 [-43.6;7.9]	-22.0* [-49.1;5.1]	-20.6 [-49.5;8.3]	-16.8 [-49.2;15.6]	-19.4 [-66.1;27.4]
	All patients (n=143)	7.2	-1.8 [-18.7;15.2]	-4.0 [-20.8;12.8]	-4.5 [-21.8;12.8]	-5.8 [-23.9;12.3]	-5.4 [-24.5;13.6]	-4.0 [-26.6;18.6]	-5.2 [-34.1;23.7]
Psycho- and neurological disorders	Patients with the comorbidity (n=44)	18.0	-5.0 [-28.5;18.6]	-5.3 [-28.8;18.3]	-2.3 [-26.8;22.2]	0.7 [-25.0;26.5]	-2.0 [-29.4;25.3]	-5.9 [-36.9;25.2]	7.7 [-29.6;44.9]
	All patients (n=143)	5.5	-1.5 [-18.4;15.5]	-1.2 [-18.0;15.6]	0.5 [-16.8;17.8]	1.6 [-16.5;19.7]	0.4 [-18.7;19.5]	-1.0 [-23.6;21.6]	5.3 [-23.6;34.2]
Total curative cost	All patients (n=143)	118.2	-42.8*** [-59.8;-25.9]	-53.3*** [-70.1;-36.5]	-54.7*** [-72.0;-37.4]	-64.9*** [-83.0;-46.8]	-74.8*** [-93.9;-55.7]	-75.0*** [-97.6;-52.4]	-68.9*** [-97.8;-40.0]

The mean difference between the medication cost per month (at each time post RYGB point compared to baseline) and the preoperative cost per month with the 95% confidence interval.

The total number of patients was 143.

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

Table 3: The different treatments for T2D before and after RYGB along the follow-up

Therapy	Baseline	1M	3M	6M	1Y	2Y	3Y	4Y
Monotherapy (n) (oral antidiabetic (OAD))	15 (31%)	7 (33%)	7 (37%)	5 (38.5%)	3 (30%)	3 (43%)	2 (67%)	0
Bitherapy (oral antidiabetic)	10 (20%)	0	2 (10%)	2 (15.5%)	3 (30%)	2 (28.5%)	1 (33%)	0
Tritherapy (oral antidiabetic)	1 (2%)	0	0	0	0	0	0	0
OAD + insulin	20 (41%)	4 (19%)	4 (21%)	3 (23%)	3 (30%)	2 (28.5%)	0	0
Insulin only	3 (6%)	10 (48%)	6 (32%)	3 (23%)	1 (10%)	0	0	0




Figure 1: Mean BMI \pm SD before and after RYGB. On the X axis is represented the number of patient at each time point of the follow-up. (*before surgery is referred as preop, 1M: 1 month, 1Y : 1 year*)




Figure 2: Medication cost per month per person pre-and post-RYGB, subdivided in preventive and curative medication use; significant differences are shown in comparison with baseline costs. (*before surgery is referred as preop, 1M: 1 month, 1Y : 1 year*), *: $p < 0.05$; ***: $p < 0.001$




Figure 3: Mean cost per patient per month for the different comorbidities, among the patients who suffer from the comorbidity. (*before surgery is referred as preop, 1M: 1 month, 1Y: 1 year*)